Worldwide Myelodysplastic Syndrome Treatment Drugs Industry to 2029 – by Drug Class and Geography – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Myelodysplastic Syndrome (MDS) Treatment Drugs Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2021 to 2029” report has been added to ResearchAndMarkets.com’s offering.

This report covers in-depth data related to MDS treatment drugs market. The report covers overall analysis related to market segments based on drug class (hypomethylating agents, immunomodulatory drugs, growth factors and other) and different geographies.

Myelodysplastic syndrome (MDS) is type of cancer and is considered as group of blood and bone marrow disorders and involves production of abnormal and immature blood cells. It is anticipated that MDS treatment drugs market will show significant market growth over the forecast period due to rising prevalence of MDS, increase in spending in the healthcare system, growing investments in R&D for MDS treatment and strong presence of ideal pipeline drugs.

Expected launch of late stage pipeline drugs such as JNJ-63935937, MLN-4924, NSC-39069 and rigosertib is anticipated to drive significant market growth over the forecast period 2021-2029.1q

Companies Mentioned

• Celator Pharmaceuticals (Jazz Pharmaceuticals plc.)
• Bayer AG
• Celgene Corporation
• Cell Therapeutics Inc.
• Daiichi Sankyo Company Ltd. Incyte Corporation
• Janssen Biotech Inc.
• MedImmune LLC (AstraZeneca)
• Millennium Pharmaceuticals (Takeda Pharmaceutical)
• Novartis AG
• Onconova Therapeutics Inc.
• Pfizer Inc.
• Taiho Pharmaceutical (Otsuka Holdings)

Key Topics Covered:

Chapter 1. Preface

Chapter 2. Executive Summary

Chapter 3. Myelodysplastic Syndrome (MDS) Treatment Drugs: Market Dynamics and Outlook

3.1. Market Definition and Overview

3.2. Drivers

3.3. Challenges

3.4. Opportunities

3.5. Attractive Investment Proposition, by Geography

3.6. Competitive Landscape

3.6.1. Competitive Landscape, by Key Players, 2020

Chapter 4. Pipeline Analysis of Myelodysplastic Syndrome (MDS) Treatment Drugs

4.1. Overview

4.2. Pipeline Analysis of Phase 3 Drugs

4.3. Tabular Presentation of Phase 1 and Phase 2 Drugs

Chapter 5. Global Myelodysplastic Syndrome (MDS) Treatment Drugs Market, by Drug Class, 2019 – 2029 (US$ Mn)

5.1. Overview

5.2. Attractive Investment Proposition, by Drug Class, 2020

5.3. Hypomethylating Agents

5.3.1. Azacitidine

5.3.2. Decitabine

5.4. Immunomodulatory Drugs

5.4.1. Lenalidomide

5.5. Growth Factors

5.5.1. Epoetin Alfa

5.5.2. Darbepoetin Alfa

5.5.3. Filgrastim

5.6. Others

5.6.1. Cytarabine

5.6.2. Daunorubicin

5.6.3. Idarubicin

5.6.4. Topotecan

5.6.5. Fludarabine

Chapter 6. Global Myelodysplastic Syndrome (MDS) Treatment Drugs Market, by Geography, 2019 – 2029 (US$ Mn)

6.1. Overview

6.2. North America Myelodysplastic Syndrome (MDS) Treatment Drugs Market Analysis, 2019 – 2029

6.2.1. North America Myelodysplastic Syndrome (MDS) Treatment Drugs Market, by Drug Class, 2019 – 2029 (US$ Mn)

6.2.2. North America Myelodysplastic Syndrome (MDS) Treatment Drugs Market, by Country, 2019 – 2029 (US$ Mn)

6.2.2.1. U.S.

6.2.2.2. Canada

6.3. Europe Myelodysplastic Syndrome (MDS) Treatment Drugs Market Analysis, 2019 – 2029

6.3.1. Europe Myelodysplastic Syndrome (MDS) Treatment Drugs Market, by Drug Class, 2019 – 2029 (US$ Mn)

6.3.2. Europe Myelodysplastic Syndrome (MDS) Treatment Drugs Market, by Country, 2019 – 2029 (US$ Mn)

6.3.2.1. U.K.

6.3.2.2. Germany

6.3.2.3. Rest of Europe

6.4. Asia Pacific Myelodysplastic Syndrome (MDS) Treatment Drugs Market Analysis, 2019 – 2029

6.4.1. Asia Pacific Myelodysplastic Syndrome (MDS) Treatment Drugs Market, by Drug Class, 2019 – 2029 (US$ Mn)

6.4.2. Asia Pacific Myelodysplastic Syndrome (MDS) Treatment Drugs Market, by Country, 2019 – 2029 (US$ Mn)

6.4.2.1. China

6.4.2.2. Japan

6.4.2.3. Rest of APAC

6.5. Latin America Myelodysplastic Syndrome (MDS) Treatment Drugs Market Analysis, 2019 – 2029

6.5.1. Latin America Myelodysplastic Syndrome (MDS) Treatment Drugs Market, by Drug Class, 2019 – 2029 (US$ Mn)

6.5.2. Latin America Myelodysplastic Syndrome (MDS) Treatment Drugs Market, by Country, 2019 – 2029 (US$ Mn)

6.5.2.1. Brazil

6.5.2.2. Mexico

6.5.2.3. Rest of Latin America

6.6. Middle East & Africa (MEA) Myelodysplastic Syndrome (MDS) Treatment Drugs Market Analysis, 2015 – 2025

6.6.1. MEA Myelodysplastic Syndrome (MDS) Treatment Drugs Market, by Drug Class, 2019 – 2029 (US$ Mn)

6.6.2. MEA Myelodysplastic Syndrome (MDS) Treatment Drugs Market, by Region, 2019 – 2029 (US$ Mn)

6.6.2.1. GCC

6.6.2.2. Rest of MEA

Chapter 7. Company Profiles

7.1. Bayer AG

7.1.1. Business Description

7.1.2. Financial Information (Subject to data availability)

7.1.3. Drug Class Portfolio

7.1.4. Key Developments

7.2. Celator Pharmaceuticals (Jazz Pharmaceuticals plc.)

7.3. Celgene Corporation

7.4. Cell Therapeutics, Inc.

7.5. Daiichi Sankyo Company, Ltd.

7.6. Incyte Corporation

7.7. Janssen Biotech, Inc.

7.8. MedImmune, LLC (AstraZeneca)

7.9. Millennium Pharmaceuticals (Takeda Pharmaceutical)

7.10. Novartis AG

7.11. Onconova Therapeutics, Inc.

7.12. Pfizer, Inc.

7.13. Taiho Pharmaceutical (Otsuka Holdings)

7.14. Other Notable Players

For more information about this report visit https://www.researchandmarkets.com/r/yfjtek

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

[email protected]

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900